Head-to-head evidence
PF-06865571 vs PF-06865571 Monotherapy
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: Diacylglycerol acyltransferase 2 (DGAT2) · full MASH / NASH pipeline
PF-06865571
Developed by Madrigal Pharmaceuticals under a licence from Pfizer
NCT04321031 · Phase 2 · completed
The trial was randomized, double-blind/double-dummy, placebo-controlled, and included 256 participants, with liver-biopsy-based NASH and fibrosis outcomes as its primary endpoints. However, the two primary analyses were discordant: Bayesian dose-response comparisons for PF-06865571 alone were not clearly positive, whereas some combination-arm comparisons were favorable, so the results support moderate rather than strong evidence.
PF-06865571 Monotherapy
Developed by Pfizer
NCT03776175 · Phase 2 · completed
Participants were randomly assigned and participants, care providers, and investigators were masked; the PF-06865571 monotherapy arm included 28 participants and was compared with 14 placebo participants. The primary MRI-PDFF endpoint was statistically favorable for PF-06865571 versus placebo, but it measured liver fat as a surrogate outcome, so the evidence is considered moderate rather than strong.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-06865571's landscape · PF-06865571 Monotherapy's landscape